Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adult (4) 4
aged (4) 4
chemotherapy (4) 4
female (4) 4
gefitinib (4) 4
hematology, oncology and palliative medicine (4) 4
humans (4) 4
index medicus (4) 4
male (4) 4
middle aged (4) 4
oncology (4) 4
aged, 80 and over (3) 3
carcinoma, non-small-cell lung - drug therapy (3) 3
carcinoma, non-small-cell lung - genetics (3) 3
carcinoma, non-small-cell lung - pathology (3) 3
disease-free survival (3) 3
erlotinib (3) 3
growth-factor receptor (3) 3
lung cancer (3) 3
lung neoplasms - drug therapy (3) 3
lung neoplasms - genetics (3) 3
lung neoplasms - pathology (3) 3
mutation (3) 3
neoplasm staging (3) 3
open-label (3) 3
1st-line treatment (2) 2
adenocarcinoma (2) 2
analysis (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
cancer (2) 2
cancer therapies (2) 2
carboplatin-paclitaxel (2) 2
care and treatment (2) 2
kaplan-meier estimate (2) 2
lung cancer, non-small cell (2) 2
lung neoplasms - mortality (2) 2
multicenter (2) 2
ovarian cancer (2) 2
protein kinase inhibitors - administration & dosage (2) 2
protein kinase inhibitors - adverse effects (2) 2
quinazolines - administration & dosage (2) 2
receptor, epidermal growth factor - genetics (2) 2
tyrosine kinase inhibitors (2) 2
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - genetics (1) 1
adenocarcinoma - mortality (1) 1
adenocarcinoma - pathology (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
benzimidazoles - administration & dosage (1) 1
benzimidazoles - adverse effects (1) 1
cancer patients (1) 1
carcinoma, non-small-cell lung - mortality (1) 1
cisplatin - administration & dosage (1) 1
clinical trials (1) 1
combination (1) 1
confidence intervals (1) 1
cyclin-dependent kinases (1) 1
deoxycytidine - administration & dosage (1) 1
deoxycytidine - analogs & derivatives (1) 1
dose-response relationship, drug (1) 1
drug administration schedule (1) 1
drug therapy (1) 1
drug-related side effects and adverse reactions - chemically induced (1) 1
drug-related side effects and adverse reactions - classification (1) 1
drug-related side effects and adverse reactions - genetics (1) 1
drug-related side effects and adverse reactions - physiopathology (1) 1
exon-21 mutations (1) 1
follow-up studies (1) 1
gemcitabine (1) 1
gene expression regulation, neoplastic (1) 1
genes, erbb-1 - genetics (1) 1
genetic aspects (1) 1
glutamates - administration & dosage (1) 1
guanine - administration & dosage (1) 1
guanine - analogs & derivatives (1) 1
heart attacks (1) 1
iii trial (1) 1
inhibitor azd6244 arry-142886 (1) 1
medical colleges (1) 1
mek1/2 inhibitor (1) 1
metastasis (1) 1
mutation - genetics (1) 1
mutations (1) 1
neoplasm invasiveness - pathology (1) 1
nsclc (1) 1
oncology, experimental (1) 1
patients (1) 1
pemetrexed (1) 1
pharmaceutical industry (1) 1
prognosis (1) 1
prolonged survival (1) 1
prospective studies (1) 1
proto-oncogene proteins - genetics (1) 1
proto-oncogene proteins p21 (1) 1
quinazolines - adverse effects (1) 1
quinazolines - therapeutic use (1) 1
radiation therapy (1) 1
randomized phase-3 trial (1) 1
ras oncogene (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
by Park, Keunchil, Prof and Tan, Eng-Huat, MD and O'Byrne, Ken, Prof and Zhang, Li, Prof and Boyer, Michael, Prof and Mok, Tony, Prof and Hirsh, Vera, Prof and Yang, James Chih-Hsin, Prof and Lee, Ki Hyeong, MD and Lu, Shun, Prof and Shi, Yuankai, MD and Kim, Sang-We, MD and Laskin, Janessa, MD and Kim, Dong-Wan, Prof and Arvis, Catherine Dubos, MD and Kölbeck, Karl, MD and Laurie, Scott A, MD and Tsai, Chun-Ming, Prof and Shahidi, Mehdi, MD and Kim, Miyoung, MD and Massey, Dan, PhD and Zazulina, Victoria, MD and Paz-Ares, Luis, MD
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 577 - 589
Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line... 
Hematology, Oncology and Palliative Medicine | TYROSINE KINASE INHIBITORS | MULTICENTER | NSCLC | ONCOLOGY | ADENOCARCINOMA | RESISTANCE | TIME | CHEMOTHERAPY | ERLOTINIB | Carcinoma, Non-Small-Cell Lung - pathology | Receptor, Epidermal Growth Factor - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Protein Kinase Inhibitors - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Drug-Related Side Effects and Adverse Reactions - genetics | Quinazolines - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Drug-Related Side Effects and Adverse Reactions - physiopathology | Drug-Related Side Effects and Adverse Reactions - classification | Tyrosine | Clinical trials | Medical colleges | Care and treatment | Lung cancer, Non-small cell | Gefitinib | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Selumetinib plus docetaxel for KRAS -mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
by Jänne, Pasi A, Dr and Shaw, Alice T, MD and Pereira, José Rodrigues, MD and Jeannin, Gaëlle, MD and Vansteenkiste, Johan, Prof and Barrios, Carlos, MD and Franke, Fabio Andre, MD and Grinsted, Lynda, MSc and Zazulina, Victoria, MD and Smith, Paul, PhD and Smith, Ian, MD and Crinò, Lucio, Prof
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 38 - 47
Summary Background No targeted therapies are available for KRAS -mutant non-small-cell lung cancer (NSCLC). Selumetinib is an inhibitor of MEK1/MEK2,... 
Hematology, Oncology and Palliative Medicine | GROWTH-FACTOR RECEPTOR | GEFITINIB | RAS ONCOGENE | ONCOLOGY | MEK1/2 INHIBITOR | INHIBITOR AZD6244 ARRY-142886 | OPEN-LABEL | MUTATIONS | COMBINATION | III TRIAL | CHEMOTHERAPY | Lung Neoplasms - drug therapy | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prospective Studies | Drug-Related Side Effects and Adverse Reactions - chemically induced | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Benzimidazoles - administration & dosage | Adult | Female | Benzimidazoles - adverse effects | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Antimitotic agents | Care and treatment | Oncology, Experimental | Research | Lung cancer, Non-small cell | Antineoplastic agents | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
by Yang, James Chih-Hsin, Prof and Wu, Yi-Long, Prof and Schuler, Martin, Prof and Sebastian, Martin, MD and Popat, Sanjay, FRCP and Yamamoto, Nobuyuki, Prof and Zhou, Caicun, Prof and Hu, Cheng-Ping, Prof and O'Byrne, Kenneth, Prof and Feng, Jifeng, Prof and Lu, Shun, Prof and Huang, Yunchao, Prof and Geater, Sarayut L, MD and Lee, Kye Young, Prof and Tsai, Chun-Ming, Prof and Gorbunova, Vera, Prof and Hirsh, Vera, Prof and Bennouna, Jaafar, Prof and Orlov, Sergey, Prof and Mok, Tony, Prof and Boyer, Michael, Prof and Su, Wu-Chou, Prof and Lee, Ki Hyeong, Prof and Kato, Terufumi, MD and Massey, Dan, MSc and Shahidi, Mehdi, MD and Zazulina, Victoria, MD and Sequist, Lecia V, MD
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 141 - 151
Summary Background We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an... 
Hematology, Oncology and Palliative Medicine | CANCER PATIENTS | CARBOPLATIN-PACLITAXEL | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | EXON-21 MUTATIONS | GEFITINIB | MULTICENTER | ONCOLOGY | OPEN-LABEL | ERLOTINIB | GEMCITABINE | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Prognosis | Follow-Up Studies | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Lung Neoplasms - genetics | Deoxycytidine - administration & dosage | Survival Rate | Mutation - genetics | Adenocarcinoma - drug therapy | Pemetrexed | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - therapeutic use | Glutamates - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Guanine - administration & dosage | Adenocarcinoma | Antimitotic agents | Chemotherapy | Lung cancer | Analysis | Genetic aspects | Antineoplastic agents | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
by Yang, James C-H, Prof and Sequist, Lecia V, MD and Geater, Sarayut Lucien, MD and Tsai, Chun-Ming, Prof and Mok, Tony Shu Kam, Prof and Schuler, Martin, Prof and Yamamoto, Nobuyuki, Prof and Yu, Chong-Jen, Prof and Ou, Sai-Hong I, MD and Zhou, Caicun, Prof and Massey, Daniel, MSc and Zazulina, Victoria, MD and Wu, Yi-Long, Prof
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 830 - 838
Summary Background Most patients with non-small-cell lung cancer tumours that have EGFR mutations have deletion mutations in exon 19 or the Leu858Arg point... 
Hematology, Oncology and Palliative Medicine | TYROSINE KINASE INHIBITORS | CARBOPLATIN-PACLITAXEL | GROWTH-FACTOR RECEPTOR | RANDOMIZED PHASE-3 TRIAL | 1ST-LINE TREATMENT | GEFITINIB | ONCOLOGY | OPEN-LABEL | PROLONGED SURVIVAL | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Confidence Intervals | Lung Neoplasms - mortality | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | Dose-Response Relationship, Drug | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Genes, erbB-1 - genetics | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.